New drug shows promise against rare eye cancer before liver surgery
NCT ID NCT07057596
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can completely eliminate cancer cells before surgery and help keep the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tebentafusp (a drug given intravenously)
What this could lead to
If successful, this could offer a new treatment option that shrinks liver tumors before surgery, potentially delaying or preventing the cancer from coming back.
What could go wrong
This is a small, early-phase trial with only 19 participants, so results may not apply to everyone. Tebentafusp can cause serious side effects, and it is not yet known if it will work better than current treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Charité - Universitätsmedizin Berlin
RECRUITINGBerlin, State of Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Consorcio Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, 46014, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital La Paz
RECRUITINGMadrid, Madrid, 28046, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Catala d'Oncologia (ICO) Hospitalet
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••